Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price increased by Wells Fargo & Company from $260.00 to $262.00 in a report published on Friday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. ASND has been the subject of a number of other reports. Cantor Fitzgerald restated […]
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price upped by Wells Fargo & Company from $260.00 to $262.00 in a research report report published on Friday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. A number of other research firms have also weighed in on ASND. […]
Analysts’ price target changes for Friday, May 3rd: Apple (NASDAQ:AAPL) had its target price increased by Canaccord Genuity Group Inc. from $200.00 to $215.00. The firm currently has a buy rating on the stock. Archer Aviation (NYSE:ACHR) had its price target lowered by JPMorgan Chase & Co. from $7.00 to $5.00. They currently have an […]
Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […]
Certuity LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,144 shares of the biotechnology company’s stock, valued at approximately $270,000. Other hedge funds also recently modified their […]